Role of HPV DNA , HPV mRNA and cytology in the follow‐up of women treated for cervical dysplasia

Apmis ◽  
2019 ◽  
Vol 127 (4) ◽  
pp. 196-201
Author(s):  
Giancarlo Tisi ◽  
Franco Gargiulo ◽  
Elisa Gozzini ◽  
Carla Baronchelli ◽  
Franco Odicino ◽  
...  
Keyword(s):  
Cervical Dysplasia ◽  
Hpv Dna ◽  
Hpv Mrna

TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 6002-6002 ◽  
Author(s):  
Joel Guigay ◽  
Jerome Fayette ◽  
Ricard Mesia ◽  
Cedrik Lafond ◽  
Esma Saada-Bouzid ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Phase Ii ◽  
Open Label ◽  
Locoregional Treatment ◽  
Significance Level ◽  
Hpv Dna ◽  
Open Label Trial ◽  
Clinical Trial Information

6002 Background: After promising results from the GORTEC TPEx phase II trial, the role of taxane instead of 5FU in 1st-line R/M HNSCC chemotherapy (CT) remained to be confirmed by comparing TPEx to the reference EXTREME regimen. Methods: Randomized (1:1), open-label trial. Main inclusion criteria were R/M HNSCC not suitable for locoregional treatment, age 18-70 years, PS <2, creatinine clearance >60ml/min, prior cisplatin <300 mg/m². Reference EXTREME regimen (arm A: 6 cycles every 3 weeks (Q3W) of 5FU–cisplatin-cetuximab (cetux) followed by weekly cetux maintenance) was compared to TPEx regimen (arm B: 4 cycles Q3W of docetaxel 75mg/m²–cisplatin 75mg/m²- cetux 250mg/m² with mandatory G-CSF support followed by every 2W cetux 500mg/m² maintenance). The primary endpoint was Overall Survival (OS). To detect a hazard ratio (HR) of 0.72 (median OS increase from 10.1 to 14.0 months (mo) with 88% power, 2-sided significance level of 0.05, 374 deaths were required. 540 patients (pts) were planned to enroll. Results: 539 pts were enrolled in 37 mo. Median age was 60 years, 93% were smokers, 40% had oropharyngeal tumor (p16 or HPV DNA was done in 85%, positive in 28%). In arm A, 44% of pts received all CT cycles vs 72% in arm B. Delays in administration were more frequent in arm A (27% vs 10%). Cisplatin was more frequently switched to carboplatin in arm A (34% vs 9%). Toxicity was lower in arm B: 34% pts had grade ≥4 adverse events during CT in arm B vs 50% in arm A (p<0.001). Less pts in arm A started maintenance than in arm B (53% vs 73%). At time of analysis, the median follow-up duration was 30 mo and 406 pts had died. OS was not significantly different between arms: HR=0.87 (95%CI: 0.71-1.05), p=0.15. Median OS was 13.4 mo in arm A vs 14.5 in arm B. 2-year OS rate was 21.0% in arm A vs 28.6% in arm B. Conclusions: This large randomized trial confirmed the encouraging survival results of the TPEx regimen observed in the first phase II. OS in both arms was higher than observed in previous randomized CT or immunotherapy combination trials. Despite lack of significant OS increase, taxane based TPEx regimen appears to be a new option in 1st line R/M HNSCC, with a shorter time on CT and significantly lower toxicity than the EXTREME regimen. Clinical trial information: NCT02268695.

scholarly journals 14-type HPV mRNA test in triage of HPV DNA positive postmenopausal women with normal cytology

2020 ◽  
Author(s):  
Katrin Christine Asciutto ◽  
Christer Borgfeldt ◽  
Ola Forslund
Keyword(s):  
Postmenopausal Women ◽  
Cervical Dysplasia ◽  
Incidence Rates ◽  
Abnormal Cytology ◽  
Surveillance Period ◽  
Normal Cytology ◽  
Hpv Dna ◽  
Luminex Assay ◽  
Increased Risk ◽  
Hpv Mrna

Abstract Background: During 2013 and 2016 the Region of Skåne, Sweden, started to analyse human papillomavirus (HPV) and cytology in postmenopausal women 60-65 years of age. Our aim was to evaluate high-risk (HR) HPV mRNA testing for the triage of HPV DNA positive postmenopausal women with normal cytology.Methods: A total of 271 women, 60-65 years of age, underwent liquid based cytology (LBC) and HPV testing by using the HR-HPV DNA MGP-PCR-Luminex assay. HR-HPV DNA-positive women with normal cytology underwent complimentary HPV mRNA testing (Aptima, Hologic Inc.). Over a period of 49 months (SD 11.0) the women received regular follow-up at intervals of 12-18 months. Women with abnormal cytology and/or a positive HR-HPV DNA and/or mRNA result at two subsequent visits were scheduled for colposcopy and clinical examination. Results: Over the surveillance period, 3.6% (10/271) of the HR-HPV DNA positive women developed histologically confirmed high-grade squamous intraepithelial lesions (HSILs) or worse. The cumulative incidence rates (CIR) were 29.7% (CI 24.8-30.1) for HSIL or worse among HPV mRNA-positive women at enrolment (39.5% 107/271) and 0% among HPV mRNA negative women (60.5%, 164/271), (p=0.002). Conclusions: Postmenopausal women with normal cytology along with the presence of HR-HPV mRNA are at increased risk for development of severe cervical dysplasia, in contrast to those women with negative HR-HPV mRNA. The HR-HPV mRNA APTIMA assay detecting 14 HR-HPV types may be a useful triage method among HPV DNA positive postmenopausal women with normal cytology.

scholarly journals Serum HPV16 E7 Oncoprotein Is a Recurrence Marker of Oropharyngeal Squamous Cell Carcinomas

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3370
Author(s):  
Lucia Oton-Gonzalez ◽  
John Charles Rotondo ◽  
Carmen Lanzillotti ◽  
Elisa Mazzoni ◽  
Ilaria Bononi ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Carcinomas ◽  
Free Survival ◽  
Hpv Dna ◽  
E7 Oncoprotein ◽  
Serological Studies ◽  
Novel Biomarkers ◽  
Hpv Mrna ◽  
Worse Prognosis

Despite improved prognosis for many HPV-positive head and neck squamous cell carcinomas (HNSCCs), some cases are still marked by recurrence and metastasis. Our study aimed to identify novel biomarkers for patient stratification. Classical HPV markers: HPV-DNA, p16 and HPV mRNA expression were studied in HNSCC (n = 67) and controls (n = 58) by qPCR. Subsequently, ELISA tests were used for HPV16 L1 antibody and HPV16 E7 oncoprotein detection in serum at diagnosis and follow-up. All markers were correlated to relapse-free survival (RFS) and overall survival (OS). HPV-DNA was found in HNSCCs (29.85%), HPV16-DNA in 95% of cases, HPV16 E7 mRNA was revealed in 93.75%. p16 was overexpressed in 75% of HPV-positive HNSCC compared to negative samples and controls (p < 0.001). Classical markers correlated with improved OS (p < 0.05). Serological studies showed similar proportions of HPV16 L1 antibodies in all HNSCCs (p > 0.05). Serum E7 oncoprotein was present in 30% HPV-positive patients at diagnosis (p > 0.05) and correlated to HNSCC HPV16 E7 mRNA (p < 0.01), whereas it was associated to worse RFS and OS, especially for oropharyngeal squamous cell carcinoma (OPSCC) (p < 0.01). Detection of circulating HPV16 E7 oncoprotein at diagnosis may be useful for stratifying and monitoring HPV-positive HNSCC patients for worse prognosis, providing clinicians a tool for selecting patients for treatment de-escalation.

scholarly journals 14-type HPV mRNA test in triage of HPV DNA positive postmenopausal women with normal cytology

2020 ◽  
Author(s):  
Katrin Christine Asciutto ◽  
Christer Borgfeldt ◽  
Ola Forslund
Keyword(s):  
Postmenopausal Women ◽  
Cervical Dysplasia ◽  
Incidence Rates ◽  
Abnormal Cytology ◽  
Surveillance Period ◽  
Normal Cytology ◽  
Hpv Dna ◽  
Luminex Assay ◽  
Increased Risk ◽  
Hpv Mrna

Abstract Background: During 2013 and 2016 the Region of Skåne, Sweden, started to analyse human papillomavirus (HPV) and cytology in postmenopausal women 60-65 years of age. Our aim was to evaluate high-risk (HR) HPV mRNA testing for the triage of HPV DNA positive postmenopausal women with normal cytology. Methods: A total of 271 women, 60-65 years of age, underwent liquid based cytology (LBC) and HPV testing by using the HR-HPV DNA MGP-PCR-Luminex assay. HR-HPV DNA-positive women with normal cytology underwent complimentary HPV mRNA testing (Aptima, Hologic Inc.). Over a period of 49 months (SD 11.0) the women received regular follow-up at intervals of 12-18 months. Women with abnormal cytology and/or a positive HR-HPV DNA and/or mRNA result at two subsequent visits were scheduled for colposcopy and clinical examination. Results: Over the surveillance period, 3.6% (10/271) of the HR-HPV DNA positive women developed histologically confirmed high-grade squamous intraepithelial lesions (HSILs) or worse. The cumulative incidence rates (CIR) were 29.7% (CI 24.8-30.1) for HSIL or worse among HPV mRNA-positive women at enrolment (39.5% 107/271) and 0% among HPV mRNA negative women (60.5%, 164/271), (p=0.002). Conclusions : Postmenopausal women with normal cytology along with the presence of HR-HPV mRNA are at increased risk for development of severe cervical dysplasia, in contrast to those women with negative HR-HPV mRNA. The HR-HPV mRNA APTIMA assay detecting 14 HR-HPV types may be a useful triage method among HPV DNA positive postmenopausal women with normal cytology.

scholarly journals Role of the HPV DNA Test in Follow-up of Treated Cervical Intraepithelial Neoplasia in Bangladesh

2014 ◽  
Vol 15 (19) ◽  
pp. 8063-8067 ◽  
Author(s):  
Ashrafun Nessa ◽  
Mohammad Harun Ur Rashid ◽  
Munira Jahan ◽  
Noor-E Ferdous ◽  
Pervin Akhter Shamsun Nahar ◽  
...  
Keyword(s):  
Cervical Intraepithelial Neoplasia ◽  
Intraepithelial Neoplasia ◽  
Dna Test ◽  
Hpv Dna ◽  
Hpv Dna Test

scholarly journals Assessing the Long-Term Role of Vaccination against HPV after Loop Electrosurgical Excision Procedure (LEEP): A Propensity-Score Matched Comparison

Vaccines ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 717
Author(s):  
Giorgio Bogani ◽  
Francesco Raspagliesi ◽  
Francesco Sopracordevole ◽  
Andrea Ciavattini ◽  
Alessandro Ghelardi ◽  
...  
Keyword(s):  
Propensity Score ◽  
Propensity Score Matching ◽  
Cervical Dysplasia ◽  
The Cost ◽  
Matched Comparison ◽  
Term Data ◽  
Loop Electrosurgical Excision

Background: Primary prevention through vaccination is a prophylactic approach aiming to reduce the risk of developing human papillomavirus (HPV)-related lesions. No mature and long-term data supported the adoption of vaccination in women undergoing conization. Methods: This is a retrospective multi-institutional study. Charts of consecutive patients undergoing conization between 2010 and 2014 were collected. All patients included had at least 5 years of follow-up. We compared outcomes of patients undergoing conization plus vaccination and conization alone. A propensity-score matching algorithm was applied in order to reduce allocation biases. The risk of developing recurrence was estimated using Kaplan-Meir and Cox hazard models. Results: Overall, charts of 1914 women were analyzed. The study group included 116 (6.1%) and 1798 (93.9%) women undergoing conization plus vaccination and conization alone, respectively. Five-year recurrence rate was 1.7% (n = 2) and 5.7% (n = 102) after conization plus vaccination and conization alone, respectively (p = 0.068). After the application of a propensity-score matching, we selected 100 patients undergoing conization plus vaccination and 200 patients undergoing conization alone. The crude number of recurrences was 2 (2%) and 11 (5.5%) for patients undergoing conization plus vaccination and conization alone, respectively (p = 0.231). Vaccination had no impact on persistent lesions (no negative examination between conization and new cervical dysplasia; p = 0.603), but reduced the risk of recurrent disease (patients who had at least one negative examination between conization and the diagnosis of recurrent cervical dysplasia; p = 0.031). Conclusions: Patients having vaccination experience a slightly lower risk of recurrence than women who had not, although not statistically significantly different. Further evidence is needed to assess the cost effectiveness of adopting vaccination in this setting.

scholarly journals 14-type HPV mRNA test in triage of HPV DNA positive postmenopausal women with normal cytology

2020 ◽  
Author(s):  
Katrin Christine Asciutto ◽  
Christer Borgfeldt ◽  
Ola Forslund
Keyword(s):  
Postmenopausal Women ◽  
Cervical Dysplasia ◽  
Incidence Rates ◽  
Abnormal Cytology ◽  
Surveillance Period ◽  
Normal Cytology ◽  
Hpv Dna ◽  
Luminex Assay ◽  
Increased Risk ◽  
Hpv Mrna

Abstract Background: During 2013 and 2016 the Region of Skåne, Sweden, started to analyse human papillomavirus (HPV) and cytology in postmenopausal women 60-65 years of age. Our aim was to evaluate high-risk (HR) HPV mRNA testing for the triage of HPV DNA positive postmenopausal women with normal cytology. Methods: A total of 271 women, 60-65 years of age, underwent liquid based cytology (LBC) and HPV testing by using the HR-HPV DNA MGP-PCR-Luminex assay. HR-HPV DNA-positive women with normal cytology underwent complimentary HPV mRNA testing (Aptima, Hologic Inc.). Over a period of 49 months (SD 11.0) the women received regular follow-up at intervals of 12-18 months. Women with abnormal cytology and/or a positive HR-HPV DNA and/or mRNA result at two subsequent visits were scheduled for colposcopy and clinical examination. Results: Over the surveillance period, 3.6% (10/271) of the HR-HPV DNA positive women developed histologically confirmed high-grade squamous intraepithelial lesions (HSILs) or worse. The cumulative incidence rates (CIR) were 29.7% (CI 24.8-30.1) for HSIL or worse among HPV mRNA-positive women at enrolment (39.5% 107/271) and 0% among HPV mRNA negative women (60.5%, 164/271), (p=0.002). Conclusions : Postmenopausal women with normal cytology along with the presence of HR-HPV mRNA are at increased risk for development of severe cervical dysplasia, in contrast to those women with negative HR-HPV mRNA. The HR-HPV mRNA APTIMA assay detecting 14 HR-HPV types may be a useful triage method among HPV DNA positive postmenopausal women with normal cytology. Key words : HR-HPV mRNA testing, cervical cancer screening, postmenopausal women

The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature

2004 ◽  
Vol 30 (2) ◽  
pp. 205-211 ◽  
Author(s):  
Evangelos Paraskevaidis ◽  
Marc Arbyn ◽  
Alexandros Sotiriadis ◽  
Emmanuel Diakomanolis ◽  
Pierre Martin-Hirsch ◽  
...  
Keyword(s):  
Systematic Review ◽  
Review Of The Literature ◽  
Dna Testing ◽  
Hpv Dna ◽  
Hpv Dna Testing

Risk of CIN2 or more severe lesions after negative HPV‐mRNA E6/E7 overexpression assay and after negative HPV‐DNA test: Concurrent cohorts with a 5‐year follow‐up

2020 ◽  
Vol 146 (11) ◽  
pp. 3114-3123 ◽  
Author(s):  
Manuel Zorzi ◽  
Annarosa Del Mistro ◽  
Paolo Giorgi Rossi ◽  
Licia Laurino ◽  
Jessica Battagello ◽  
...  
Keyword(s):  
Dna Test ◽  
Hpv Dna ◽  
Hpv Mrna ◽  
Hpv Dna Test

Lack of type-specific concordance between human papillomavirus (HPV) serology and HPV DNA detection in the uterine cervix and oral mucosa

2011 ◽  
Vol 92 (9) ◽  
pp. 2034-2046 ◽  
Author(s):  
A. E. Paaso ◽  
K. Louvanto ◽  
K. J. Syrjänen ◽  
T. Waterboer ◽  
S. E. Grénman ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Uterine Cervix ◽  
Dna Detection ◽  
Serological Response ◽  
Hpv Dna ◽  
Oral Hpv ◽  
Antibody Levels ◽  
Hpv16 Infection

There is limited knowledge about longitudinal genotype-specific concordance between human papillomavirus (HPV) serology and co-existent presence of HPV DNA in the uterine cervix. The role of oral HPV infections in inducing serological response is unclear, as is the effect of HPV antibodies on the outcome of oral HPV infections. The present study is part of the Finnish Family HPV Study designed to evaluate dynamics of HPV infections within families. Here, we correlated the point prevalence of HPV6, 11, 16, 18 and 45 antibodies and concomitant genotype-specific HPV DNA detection in cervical and oral samples of 323 mothers during their 3 year (mean 37.5 months) follow-up. The mean age of these pregnant mothers at enrolment (third trimester) was 25.5 years. HPV antibodies were analysed with multiplex HPV serology and HPV genotyping was performed using a Multimetrix kit (Progen Biotechnik). There was no concordance between cervical DNA detection and co-existent seropositivity, and the same was true even in samples taken 12 months apart. Women who cleared their cervical HPV16 infection had the highest HPV16 antibody levels, whereas those who acquired incident HPV16 infections had the lowest antibody levels. Neither the presence nor the dynamics of oral HPV DNA had any correlation with HPV serology.

Sign in / Sign up

Export Citation Format

Share Document